Aquestive Therapeutics (AQST) closed at $2.39 in the latest trading session, marking a +0.84% move from the prior day. The stock's performance was ahead of the S&P 500's daily loss of 0.07%. Elsewhere, the Dow gained 0.16%, while the tech-heavy Nasdaq lost 0.36%.Shares of the specialty pharmaceutical company have appreciated by 18.5% over the course of the past month, outperforming the Medical sector's gain of 1.45% and the S&P 500's gain of 3.05%.The investment community will be closely monitoring the perf ...

The latest trading session saw Aquestive Therapeutics (AQST) ending at $2.50, denoting a -0.4% adjustment from its last day's close. This change lagged the S&P 500's 0.29% gain on the day. On the other hand, the Dow registered a loss of 0.25%, and the technology-centric Nasdaq increased by 0.43%.The the stock of specialty pharmaceutical company has risen by 25.5% in the past month, leading the Medical sector's gain of 2.29% and the S&P 500's gain of 2.08%.The investment community will be closely monitoring ...

Flex Point Security Aquestive Therapeutics (NASDAQ:AQST) is quickly approaching a key topline data readout for the Anaphylm (epinephrine) sublingual film that is slated for Q1 of this year. The company announced in December that they have commenced the first patient dosing in its Phase III pivotal study evaluating Anaphylm’s pharmacokinetics “PK” and pharmacodynamics “PD”. If the data is positive, Anaphylm would be heading towards a possible NDA in 2024 as a groundbreaking oral epinephrine candidate in ...

In the latest trading session, Aquestive Therapeutics (AQST) closed at $2.63, marking a -1.13% move from the previous day. This change lagged the S&P 500's 0.56% loss on the day. Elsewhere, the Dow saw a downswing of 0.25%, while the tech-heavy Nasdaq depreciated by 0.59%.The the stock of specialty pharmaceutical company has risen by 34.77% in the past month, leading the Medical sector's gain of 3.8% and the S&P 500's gain of 1.2%.Market participants will be closely following the financial results of Aquest ...

Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q3 2023 Earnings Conference Call November 7, 2023 8:00 AM ET Company Participants Bennett Watson - Investor Relations, ICR Westwicke Dan Barber - Chief Executive Officer Ernie Toth - Senior Vice President & Chief Financial Officer Steve Wargacki - Senior Vice President, Research & Development Ken Marshall - Senior Vice President & Chief Commercial Officer Carl Kraus - Chief Medical Officer Conference Call Participants Jason Butler - JMP Securities François Briseboi ...

Q3 2023 Earnings Supplemental Materials November 6, 2023 Advancing medicines. Solving problems. Improving lives. 1 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number: 001-38599 Aquestive Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) (State or other jurisdiction of ...

Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q2 2023 Earnings Conference Call August 8, 2023 8:00 AM ET Company Participants Bennett Watson - Investor Relations, ICR Westwicke Dan Barber - Chief Executive Officer Ernie Toth - Senior Vice President, Chief Financial Officer Steve Wargacki - Senior Vice President, Research and Development Ken Marshall - Senior Vice President, Chief Commercial Officer Carl Kraus - Chief Medical Officer Conference Call Participants Jason Butler - JMP François Brisebois - Oppenheim ...

Q2 2023 Earnings Supplemental Materials August 7, 2023 Advancing medicines. Solving problems. Improving lives. ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number: 001-38599 Aquestive Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) (State or other jurisdiction of Incor ...